Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 6,024 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 6,024 shares of the firm’s stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total value of $143,672.40. Following the completion of the sale, the general counsel now directly owns 143,830 shares in the company, valued at approximately $3,430,345.50. This represents a 4.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Phreesia Stock Up 0.3 %

Shares of NYSE:PHR opened at $24.06 on Friday. The firm has a market cap of $1.41 billion, a P/E ratio of -16.37 and a beta of 0.82. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The business has a fifty day simple moving average of $26.57 and a 200 day simple moving average of $24.26. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Johnson Financial Group Inc. boosted its holdings in Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after acquiring an additional 896 shares during the last quarter. R Squared Ltd bought a new position in Phreesia during the fourth quarter worth $30,000. BankPlus Trust Department acquired a new position in shares of Phreesia during the fourth quarter valued at about $34,000. Quarry LP boosted its position in shares of Phreesia by 210.9% during the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock worth $71,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Phreesia in the 4th quarter valued at about $76,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

PHR has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Piper Sandler restated an “overweight” rating and issued a $33.00 price target (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Canaccord Genuity Group boosted their target price on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Finally, KeyCorp increased their price target on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.